EMA confirms abemaciclib benefit in hormone-sensitive breast cancer

European Medicines Agency validates abemaciclib for hormone receptor-positive breast cancer.

Published 17sem1 sourceNotableupdated 3sem

≈ 11sSpeed

The fact

New therapeutic option for patients with this tumor type.

Click the link to read an article on the topic:

Explore this topic

EMA approuve abémaciclib cancer du sein hormonosensible

May 1EMA confirms abemaciclib benefit in hormone-sensitive breast cancerthis article

Auto-synthesis from 1 media source · identified on May 1, 2026